The DNA Microarray and Homology Modeling Core will have several major functions. First it will be a resource for laboratories to examine how exposure to toxic agents affects gene expression. Laboratories will discus with Core personnel (Project Leaders, Senior Investigators, or PGR) projected experiments so that practical plans can be developed. Such discussion will lead to discussions whether a given problem is addressed best (a) by generating a limited cDNA array by subtractive hybridization, (b) using a subset of cDNAs available in the Core repository, or (c) through a full array of cDNAs available in the repository. When a subtractively hybridized array is considered the appropriate approach, the Core will assist in its generation by representational difference analysis, a technique with which Dr. Gregg (Senior Investigator) has much experience. As the Core expands its repository of cDNA clones, the emphasis is anticipated to shift gradually to larger arrays. This will be true particularly in the case of human genes, for which we already have at our disposal nearly 10,000 clones through the effects of Dr. Wu (Senior Investigator) and colleagues. The Core will prepare arrays for Superfund experiments, conduct the hybridization and scanning, present the results to the labs and help with the interpretations. A second major function of the Core will be in 3-D homology modeling. This will permit Superfund investigators to examine protein-toxicant interactions electronically, thereby gaining valuable mechanistic information that can be applied to other potential targets. The third major junction of the Core is in bioinformatics. This will consist largely of data management, assisting Superfund investigators with data analysis and database searchers and helping investigators utilize the campus Life Sciences Informatics Program. Initial data handling will be in this core. As data sets become larger they will be transferred to the Statistics Core B.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-16
Application #
6580387
Study Section
Special Emphasis Panel (ZES1)
Project Start
2002-04-01
Project End
2003-03-31
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
$165,230
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications